L-DOPA (sodium)

• UNSPSC Description:

  L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson's disease research[1][2][3].

• Target Antigen:

  Dopamine Receptor; Endogenous Metabolite

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Metabolic Enzyme/Protease;Neuronal Signaling

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/l-dopa-sodium.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C([C@H](CC1=CC=C(C(O)=C1)O)N)O[Na]

• Molecular Weight:

  219.17

• References & Citations:

  [1]Hyland K, et al. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992 Dec;38(12):2405-10.|[2]Merims D, et al. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. Parkinsonism Relat Disord. 2008;14(4):273-80. Epub 2007 Nov 7.|[3]Perez-Pardo P, et al. Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson's Disease. Front Aging Neurosci. 2018 Aug 3;10:237.|[4]Park HJ, et al. Anti-allodynic effects of levodopa in neuropathic rats. Yonsei Med J. 2013 Mar 1;54(2):330-5.|[5]M Lundblad, et al. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol. 2005 Jul;194(1):66-75. |[6]Jie Zhang, et al. Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets. Brain Res. 2003 Dec 12;993(1-2):54-8.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Launched

• CAS Number:

  63302-01-2